This mini-review highlights the latest advancements in tumor immunotherapy, with a focus on cellular therapies, and addresses the resistance mechanisms that hinder their effectiveness in lung and ...

Despite recent advances in therapy, certain subtypes of colorectal cancer, such as those that are microsatellite instability (MSI-high), mismatch repair deficient (dMMR) or tumor mutation burden high ...

Objective: To build a new prognostic risk assessment model based on immune cell co-expression networks for predicting overall survival and evaluating the efficacy of immunotherapy for colon cancer ...

Neoadjuvant PD-1 blockade in mismatch repair-deficient or microsatellite instability-high, locally advanced and resectable colorectal cancer: A retrospective real-world analysis. This is an ASCO ...

Landscape of MET genomic alterations in colorectal cancer (CRC). VEGF-A as a prognostic indicator in advanced gastric and colorectal cancers and correlation with immune suppression involving ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

This is a colostomy. Immunotherapy is a key treatment for either early or advanced stage colorectal cancer. Drugs called immune checkpoint inhibitors target proteins that normally prevent the ...

Racial and ethnic disparities were identified in immunotherapy receipt for Black patients with metastatic triple-negative ...

Colorectal cancer (CRC), which affects the colon or rectum, represents a significant public health challenge. It ranks as the ...

The CheckMate 8HW trial is the first to compare single-agent immunotherapy to dual-agent immunotherapy in the first-line metastatic colorectal cancer setting. The trial included 582 patients who ...